Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On 12 May 2026, Dr. Reddy’s Laboratories disclosed to the U.S. SEC that it had published its audited financial results for the quarter and full year ended 31 March 2026, making IFRS and Ind AS consolidated and standalone statements publicly available and confirming unmodified audit opinions. The same day, the board approved a final dividend of INR 8 per share for FY 2025-26, scheduled its 42nd AGM for 23 July 2026, cleared the reappointment of independent director Dr. K.P. Krishnan and the appointment of independent director-designate Srikanth Velamakanni, and reshaped its assurance and leadership structure by naming Deloitte Haskins & Sells as statutory auditor, reappointing Sagar & Associates as cost auditor, and elevating Global Generics India head Sandeep Khandelwal to senior management.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based multinational pharmaceutical company focused on generics, branded generics and active pharmaceutical ingredients, serving regulated markets including India, the U.S. and other global regions. Listed in Mumbai, on the National Stock Exchange of India and on the New York Stock Exchange, it operates under IFRS and Indian Accounting Standards, reflecting a strong international investor base and compliance framework.
Average Trading Volume: 2,375,381
Technical Sentiment Signal: Hold
Current Market Cap: $11.29B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.